Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. It also develops lebrikizumab, a novel injectable humanized monoclonal antibody targeting interleukin 13 that is in Phase IIb clinical trial for the treatment of moderate-to-severe atopic dermatitis; and early-stage research and development programs in other areas of dermatology.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-421-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.34 million
Profitability
Miscellaneous
Employees333
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Dermira (NASDAQ:DERM) Frequently Asked Questions
What is Dermira's stock symbol?
Dermira trades on the NASDAQ under the ticker symbol "DERM."
How were Dermira's earnings last quarter?
Dermira Inc (NASDAQ:DERM) posted its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.90) by $0.57. The biopharmaceutical company had revenue of $66.65 million for the quarter, compared to analyst estimates of $34.16 million. Dermira had a negative net margin of 306.91% and a negative return on equity of 478.29%. View Dermira's Earnings History.
When is Dermira's next earnings date?
What price target have analysts set for DERM?
9 analysts have issued 12 month price targets for Dermira's stock. Their predictions range from $6.71 to $25.00. On average, they anticipate Dermira's share price to reach $18.7138 in the next twelve months. This suggests a possible upside of 116.8% from the stock's current price. View Analyst Price Targets for Dermira.
What is the consensus analysts' recommendation for Dermira?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dermira in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dermira.
What are Wall Street analysts saying about Dermira stock?
Here are some recent quotes from research analysts about Dermira stock:
- 1. According to Zacks Investment Research, "Dermira, Inc. is a specialty biopharmaceutical company. It is focused on bringing medical dermatology products to dermatologists and their patients. The Company markets topical small molecule therapeutics that target acne, sebaceous gland hyperactivity, and inflammatory skin diseases. Its late-stage product candidates comprise Cimzia which has completed Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; DRM04 that is in a Phase IIb clinical trial for the treatment of hyperhidrosis or excessive sweating; and DRM01 which has completed a Phase IIa clinical trial for the treatment of acne. Dermira, Inc. is headquartered in Redwood City, California. " (8/13/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $7 price target. The STING program currently contributes approximately 53% to our valuation (no contribution from early stage Lilly program currently) and the APRIL program approximately 43%, with the remainder coming from the anti-CD27 program being developed by Merck (MRK; not rated). Our target is based on our clinical net present value (NPV) model. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (5/8/2019)
- 3. Cantor Fitzgerald analysts commented, "DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25." (5/3/2019)
Has Dermira been receiving favorable news coverage?
News headlines about DERM stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dermira earned a news impact score of 2.5 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Dermira.
Are investors shorting Dermira?
Dermira saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 3,706,000 shares, a decrease of 22.8% from the June 30th total of 4,798,700 shares. Based on an average trading volume of 680,200 shares, the short-interest ratio is currently 5.4 days. Currently, 11.6% of the shares of the company are short sold. View Dermira's Current Options Chain.
Who are some of Dermira's key competitors?
Some companies that are related to Dermira include Cambrex (CBM), Portola Pharmaceuticals (PTLA), Apellis Pharmaceuticals (APLS), Ligand Pharmaceuticals (LGND), Tricida (TCDA), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Nabriva Therapeutics (NBRV), Corcept Therapeutics (CORT), Heron Therapeutics (HRTX), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN) and Enanta Pharmaceuticals (ENTA).
What other stocks do shareholders of Dermira own?
Who are Dermira's key executives?
Dermira's management team includes the folowing people:
- Mr. Thomas G. Wiggans, Co-Founder, CEO & Chairman (Age 67)
- Dr. Eugene Andrew Bauer, Co-Founder, Chief Medical Officer & Director (Age 77)
- Mr. Andrew L. Guggenhime, Chief Financial Officer (Age 51)
- Ms. Lori Lyons-Williams, Chief Commercial Officer (Age 42)
- Mr. Christopher M. Griffith, Co-Founder and Chief Bus. & Strategy Officer (Age 43)
Who are Dermira's major shareholders?
Dermira's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.29%), Bank of America Corp DE (3.87%), Oracle Investment Management Inc. (3.24%), JPMorgan Chase & Co. (1.46%), Sofinnova Investments Inc. (1.21%) and Earnest Partners LLC (1.08%). Company insiders that own Dermira stock include Christopher M Griffith, David E Cohen, Eugene A Bauer, Matthew K Fust and Thomas G Wiggans. View Institutional Ownership Trends for Dermira.
Which institutional investors are selling Dermira stock?
DERM stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Bank of America Corp DE, Balyasny Asset Management LLC, Renaissance Technologies LLC, Parametric Portfolio Associates LLC, Cubist Systematic Strategies LLC, First Midwest Bank Trust Division and Morgan Stanley. Company insiders that have sold Dermira company stock in the last year include Eugene A Bauer and Matthew K Fust. View Insider Buying and Selling for Dermira.
Which institutional investors are buying Dermira stock?
DERM stock was bought by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., JPMorgan Chase & Co., Man Group plc, Eversept Partners LP, Vanguard Group Inc., Sofinnova Investments Inc., Fosun International Ltd and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Dermira.
How do I buy shares of Dermira?
Shares of DERM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dermira's stock price today?
One share of DERM stock can currently be purchased for approximately $8.63.
How big of a company is Dermira?
Dermira has a market capitalization of $469.47 million and generates $42.34 million in revenue each year. The biopharmaceutical company earns $-221,540,000.00 in net income (profit) each year or ($5.24) on an earnings per share basis. Dermira employs 333 workers across the globe.View Additional Information About Dermira.
What is Dermira's official website?
How can I contact Dermira?
Dermira's mailing address is 275 Middlefield Road Suite150, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-421-7200 or via email at [email protected]
MarketBeat Community Rating for Dermira (NASDAQ DERM)
MarketBeat's community ratings are surveys of what our community members think about Dermira and other stocks. Vote "Outperform" if you believe DERM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DERM will underperform the S&P 500 over the long term. You may vote once every thirty days.
